MNKD MannKind Corporation - Common Stock
$4,34
Kurs · Aug 20, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$2–$7
49% of range
Analystenbewertung
BUY
14 analysts
Kursziel
$8
+84% upside
P/E (TTM)
216.8
ROE
-11.1%
Nettogewinnmarge
1.7%
Über MannKind Corporation - Common Stock Unternehmensübersicht von Wikipedia
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Mehr lesen
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
MNKD Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.33
Marktkapitalisierung
$1.33B
P/E (TTM)
216.8
EPS (TTM)
$0.02
Umsatz (TTM)
$349M
Dividendenrendite
—
ROE
-11.1%
Verschuldungsgrad
—
52W-Spanne
$2 – $7
MNKD Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$349M
2016-12-31
→
2025-12-31
EPS
$0.02
2016-12-31
→
2025-12-31
Freier Cashflow
$14M
2018-12-31
→
2025-12-31
Margen
1.7%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
MNKD
Peer-Median
P/E (TTM)
216.8
—
P/S (TTM) (K/V (TTM))
3.8
10.7
P/B (K/B)
-26.2
5.2
Price / FCF (Kurs / FCF)
97.5
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
MNKD
Peer-Median
Operating Margin (Betriebsgewinnmarge)
11.1%
—
Net Profit Margin (Nettogewinnmarge)
1.7%
-140.3%
ROA
0.99%
-44.7%
ROE
-11.1%
-51.5%
ROIC
-316.9%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
MNKD
Peer-Median
Current Ratio (Liquiditätsgrad)
1.7
9.5
Quick Ratio
1.2
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
MNKD
Peer-Median
Revenue YoY (Umsatz YoY)
22.2%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
51.8%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
39.9%
—
EPS YoY (EPS VjV)
-80.0%
—
Net Income YoY (Nettogewinn YoY)
-78.8%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
MNKD
Peer-Median
MNKD Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
14 Analysten
- Starker Kauf 4 28,6%
- Kauf 8 57,1%
- Halten 2 14,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
8 Analysten · 2026-08-17
Median
$7.50
← Unter allen Zielen
$4.33
Tief
$4.75
Hoch
$13.00
Median-Ziel
$7.50
+73,0%
Mittelwert-Ziel
$7.97
+83,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.03%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.06 | $-0.00 | -0.06% |
| 31. März 2026 | $-0.05 | $-0.00 | -0.05% |
| 31. Dezember 2025 | $-0.05 | $0.01 | -0.06% |
| 30. September 2025 | $0.07 | $0.02 | 0.05% |
| 30. Juni 2025 | $0.00 | $0.05 | -0.05% |
| 31. März 2025 | $0.04 | $0.04 | -0.00% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | — |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | — |
| AVBP | $854M | -4.7 | — | — | -59.7% | — |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | — |
| CGEM | $624M | -3.2 | — | — | -44.0% | — |
| JBIO | $761M | -4.8 | — | — | -47.7% | — |
| REPL | $633M | -2.3 | — | — | -146.2% | — |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | — |
| AKTS | — | — | — | — | — | — |
| GLUE | $1.03B | — | 63.5% | -31.2% | -15.4% | — |
| CRVS | $575M | -14.5 | — | — | -21.6% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
Bilanz 28
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
Cashflow 18
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
Wachstumsraten 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | -609,602,000 | 306,806,000 | 304,954,000 | 303,481,000 | -543,995,000 | 274,998,000 | 273,056,000 | 270,356,000 | -531,313,000 | 268,732,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | -629,907,000 | 311,638,000 | 311,484,000 | 320,897,000 | -598,638,000 | 284,693,000 | 273,056,000 | 324,733,000 | -586,351,000 | 323,770,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
Bilanz 25
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
Cashflow 11
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | 3.1 | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
Bewertung (TTM) 9
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $327M | · | $307M | $297M | $287M | · | $260M | $239M | $207M | · | $173M | $141M | $104M | · | $86M | |
| Net Income TTM | $-27M | $5M | · | $33M | $23M | $33M | · | $22M | $5M | $-3M | · | $-28M | $-59M | $-79M | · | $-74M | |
| Market Cap | $1.32B | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | 122.5 | · | 48.8 | 53.4 | 45.7 | · | 78.6 | 261.0 | -453.0 | · | -37.5 | -17.7 | -13.2 | · | -10.7 | |
| P/S | 3.7 | 2.3 | · | 5.4 | 3.9 | 5.3 | · | 6.7 | 6.0 | 5.9 | · | 6.4 | 7.7 | 10.4 | · | 9.5 | |
| P/B | -19.6 | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| P / FCF | · | -104.5 | · | · | · | -227.9 | · | · | · | 285.6 | · | · | · | -151.4 | · | · | |
| Earnings Yield | -1.9% | 0.82% | · | 2.1% | 1.9% | 2.2% | · | 1.3% | 0.38% | -0.22% | · | -2.7% | -5.7% | -7.6% | · | -9.4% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $349M | $286M | $199M | $100M | $75M |
| Betriebsgewinnmarge % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| Nettoergebnis | $6M | $28M | $-12M | $-87M | $-81M |
| Verwässerte EPS | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $14M | $33M | $-8M | $-88M | $-73M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
- Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
- MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
- H.C. Wainwright und Wells Fargo erhöhen die Kursziele für MannKind (MNKD)
- Ist MannKind Corporation (MNKD) eine der beliebten Penny Stocks auf Robinhood zum Kaufen?
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 273 Einreicher · $560.8M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 49 (-2 vs. Vorquartal) | 38 (-9 vs. Vorquartal) | 96 (+12 vs. Vorquartal) | 62 (-7 vs. Vorquartal) | +5.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Rubric Capital Management LP | $76.680.000 | 18.000.000 | 13,67% | Aktien |
| STATE STREET CORP | $68.901.423 | 16.174.043 | 12,29% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $56.101.610 | 13.169.392 | 10,00% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $29.027.881 | 6.812.460 | 5,18% | Aktien |
| Frazier Life Sciences Management, L.P. | $28.116.000 | 6.600.000 | 5,01% | Aktien |
| Deep Track Capital, LP | $25.560.000 | 6.000.000 | 4,56% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $23.099.232 | 5.422.355 | 4,12% | Aktien |
| 180 WEALTH ADVISORS, LLC | $21.126.835 | 4.959.351 | 3,77% | Aktien |
| FMR LLC | $17.455.563 | 4.097.550 | 3,11% | Aktien |
| TSP Capital Management Group, LLC | $16.923.596 | 3.972.675 | 3,02% | Aktien |
| BRAIDWELL LP | $14.732.908 | 3.458.429 | 2,63% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.789.240 | 3.002.169 | 2,28% | Aktien |
| VANGUARD GROUP INC | $11.888.249 | 2.096.693 | 2,12% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $11.475.213 | 2.693.712 | 2,05% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.070.577 | 2.598.727 | 1,97% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $9.358.279 | 2.196.779 | 1,67% | Aktien |
| BANK OF AMERICA CORP /DE/ | $8.689.749 | 2.039.847 | 1,55% | Aktien |
| GOLDMAN SACHS GROUP INC | $6.332.618 | 1.486.530 | 1,13% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.030.221 | 1.180.803 | 0,90% | Aktien |
| BlackRock, Inc. | $4.766.748 | 1.118.955 | 0,85% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $4.486.321 | 1.053.127 | 0,80% | Aktien |
| Caption Management, LLC | $4.260.000 | 1.000.000 | 0,76% | Verkaufsoption |
| J. Goldman & Co LP | $3.478.669 | 816.589 | 0,62% | Aktien |
| WELLS FARGO & COMPANY/MN | $3.473.987 | 815.490 | 0,62% | Aktien |
| SCOPIA CAPITAL MANAGEMENT LP | $2.960.534 | 694.961 | 0,53% | Aktien |
| Balyasny Asset Management L.P. | $2.914.296 | 684.107 | 0,52% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.897.166 | 510.964 | 0,52% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $2.771.407 | 650.565 | 0,49% | Aktien |
| Swiss National Bank | $2.502.324 | 587.400 | 0,45% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.177.052 | 511.045 | 0,39% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2.106.540 | 494.493 | 0,38% | Aktien |
| 1492 Capital Management LLC | $2.052.136 | 481.722 | 0,37% | Aktien |
| Mariner, LLC | $2.020.189 | 474.236 | 0,36% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.836.597 | 431.126 | 0,33% | Aktien |
| Schonfeld Strategic Advisors LLC | $1.774.216 | 416.483 | 0,32% | Aktien |
| Squarepoint Ops LLC | $1.759.644 | 413.062 | 0,31% | Aktien |
| Jefferies Financial Group Inc. | $1.694.202 | 397.700 | 0,30% | Aktien |
| ExodusPoint Capital Management, LP | $1.666.261 | 391.141 | 0,30% | Aktien |
| JANE STREET GROUP, LLC | $1.658.418 | 389.300 | 0,30% | Kaufoption |
| Man Group plc | $1.624.023 | 381.226 | 0,29% | Aktien |
| RHUMBLINE ADVISERS | $1.604.647 | 376.681 | 0,29% | Aktien |
| IEQ CAPITAL, LLC | $1.544.607 | 362.584 | 0,28% | Aktien |
| CITIGROUP INC | $1.499.243 | 351.935 | 0,27% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.423.692 | 334.200 | 0,25% | Verkaufsoption |
| Bank of New York Mellon Corp | $1.422.222 | 333.855 | 0,25% | Aktien |
| Caption Management, LLC | $1.414.231 | 331.979 | 0,25% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $1.359.221 | 319.066 | 0,24% | Aktien |
| ALPS ADVISORS INC | $1.330.615 | 312.351 | 0,24% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.216.230 | 285.500 | 0,22% | Kaufoption |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.029.075 | 241.567 | 0,18% | Aktien |
| BARCLAYS PLC | $1.029.062 | 241.564 | 0,18% | Aktien |
| Rafferty Asset Management, LLC | $1.008.640 | 236.770 | 0,18% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $1.002.715 | 235.379 | 0,18% | Aktien |
| Aaron Wealth Advisors LLC | $1.000.878 | 234.948 | 0,18% | Aktien |
| HSBC HOLDINGS PLC | $998.560 | 230.881 | 0,18% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $930.294 | 379.712 | 0,17% | Aktien |
| CITADEL ADVISORS LLC | $928.680 | 218.000 | 0,17% | Kaufoption |
| CITADEL ADVISORS LLC | $898.860 | 211.000 | 0,16% | Verkaufsoption |
| Bruce & Co., Inc. | $831.011 | 195.073 | 0,15% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $775.060 | 181.939 | 0,14% | Aktien |
| MetLife Investment Management, LLC | $766.442 | 179.916 | 0,14% | Aktien |
| FRANKLIN RESOURCES INC | $755.021 | 177.235 | 0,13% | Aktien |
| Stonepine Capital Management, LLC | $750.000 | 250.000 | 0,13% | Kaufoption |
| UBS Group AG | $715.978 | 168.070 | 0,13% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $693.375 | 283.010 | 0,12% | Aktien |
| MORGAN STANLEY | $651.282 | 152.883 | 0,12% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $640.657 | 150.389 | 0,11% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $632.009 | 148.359 | 0,11% | Aktien |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $613.437 | 171.372 | 0,11% | Aktien |
| Jain Global LLC | $604.673 | 141.942 | 0,11% | Aktien |
| KING LUTHER CAPITAL MANAGEMENT CORP | $590.457 | 138.605 | 0,11% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $574.538 | 134.868 | 0,10% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $570.354 | 133.886 | 0,10% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $557.723 | 130.921 | 0,10% | Aktien |
| PROFUND ADVISORS LLC | $517.726 | 121.532 | 0,09% | Aktien |
| Invesco Ltd. | $512.389 | 120.279 | 0,09% | Aktien |
| Vanguard Global Advisers, LLC | $509.833 | 119.679 | 0,09% | Aktien |
| KLP KAPITALFORVALTNING AS | $491.604 | 115.400 | 0,09% | Aktien |
| Gotham Asset Management, LLC | $452.463 | 106.212 | 0,08% | Aktien |
| State of New Jersey Common Pension Fund D | $403.171 | 94.641 | 0,07% | Aktien |
| State of Wyoming | $403.149 | 94.636 | 0,07% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $386.834 | 90.806 | 0,07% | Aktien |
| Amundi | $374.310 | 87.866 | 0,07% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $373.478 | 87.671 | 0,07% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $359.966 | 84.499 | 0,06% | Aktien |
| ARIZONA STATE RETIREMENT SYSTEM | $344.050 | 80.763 | 0,06% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338.155 | 79.379 | 0,06% | Aktien |
| Aquatic Capital Management LLC | $335.300 | 78.709 | 0,06% | Aktien |
| Rockefeller Capital Management L.P. | $332.996 | 78.168 | 0,06% | Aktien |
| Vanguard Investments Australia, Ltd. | $314.929 | 73.927 | 0,06% | Aktien |
| JANUS HENDERSON GROUP PLC | $313.658 | 127.763 | 0,06% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $312.203 | 73.287 | 0,06% | Aktien |
| Sequoia Financial Advisors, LLC | $296.935 | 69.703 | 0,05% | Aktien |
| INTECH INVESTMENT MANAGEMENT LLC | $284.653 | 66.820 | 0,05% | Aktien |
| COMMONWEALTH EQUITY SERVICES, LLC | $280.421 | 65.827 | 0,05% | Aktien |
| China Universal Asset Management Co., Ltd. | $262.714 | 61.670 | 0,05% | Aktien |
| LPL Financial LLC | $260.060 | 61.047 | 0,05% | Aktien |
| SIMPLEX TRADING, LLC | $258.790 | 60.749 | 0,05% | Aktien |
| Cetera Investment Advisers | $241.546 | 56.701 | 0,04% | Aktien |
| Painted Porch Advisors LLC | $227.620 | 53.432 | 0,04% | Aktien |
Unternehmensinsider 43 Insider · 27 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 15. Juli 2026 M | 2.433.779 | 1 | 4 | $-990.292 |
| Hakan Edstrom | President & CEO | 27. August 2015 A | 1.114.340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 15. Juli 2026 F | 318.668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 27. August 2015 A | 106.539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 15. Juli 2026 F | 343.398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 15. Juli 2026 M | 478.966 | 0 | 1 | $-94.448 |
| Stuart A Tross | Chief People & Workpl Officer | 15. Juli 2026 M | 1.058.142 | 0 | 2 | $-548.528 |
| David Thomson | EVP Genl Counsel & Secretary | 15. Juli 2026 M | 797.554 | 0 | 3 | $-930.755 |
| Ajay Ahuja | Chief Medical Officer | 23. März 2026 A | 318.200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 15. Juli 2025 F | 349.841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 15. Juli 2025 F | 460.791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 27. August 2022 F | 745.233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 28. Februar 2022 A | 576.690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 27. August 2020 A | 167.119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 31. Juli 2020 P | 41.059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 25. Februar 2020 A | 83.972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 31. Juli 2019 P | 29.584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 14. Mai 2019 A | 43.012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 10. August 2017 S | 2.924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 18. Februar 2016 A | 92.200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 22. August 2015 F | 1.005.990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 23. Februar 2015 F | 50.624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 3. März 2012 F | 133.611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 16. November 2008 F | 204.401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 13. August 2008 A | 14.650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 8. Dezember 2006 A | 14.800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 19. August 2004 A | 300 | 0 | 0 | $0 |
| Sabrina Kay | Direktor | 20. Mai 2026 A | 265.600 | 0 | 0 | $0 |
| Jennifer Grancio | Direktor | 20. Mai 2026 A | 244.815 | 0 | 0 | $0 |
| James Samuel Shannon | Direktor | 20. Mai 2026 A | 64.635 | 0 | 0 | $0 |
| Michael A Friedman | Direktor | 20. Mai 2026 A | 47.500 | 0 | 0 | $0 |
| Anthony C Hooper | Direktor | 20. Mai 2026 A | 236.153 | 0 | 0 | $0 |
| Christine Mundkur | Direktor | 20. Mai 2026 A | 254.493 | 0 | 0 | $0 |
| Ronald J Consiglio | Direktor | 20. Mai 2026 A | 132.342 | 0 | 0 | $0 |
| Kent Kresa | Direktor | 15. Mai 2024 A | 274.541 | 0 | 0 | $0 |
| Henry L Nordhoff | Direktor | 14. Mai 2019 A | 103.426 | 0 | 0 | $0 |
| David Maccallum | Direktor | 16. Mai 2018 A | 114.790 | 0 | 0 | $0 |
| Matthew J Pfeffer | Direktor | 28. August 2017 F | 81.961 | 0 | 0 | $0 |
| Abraham E Cohen | Direktor | 17. August 2012 S | 56.424 | 0 | 0 | $0 |
| Heather Hay Murren | Direktor | 13. August 2008 A | 10.100 | 0 | 0 | $0 |
| Kathleen Connell | Direktor | 25. Mai 2006 A | — | 0 | 0 | $0 |
| Llew Keltner | Direktor | 25. Mai 2006 A | — | 0 | 0 | $0 |
| Steven B. Binder | — | 7. August 2026 S | 785.867 | 0 | 3 | $-427.369 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 Einreichungen | 10. Juli 2012 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 31. Januar 2006 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 42 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| RNIN · EA Series Trust | 1,43% | 773.251 NS | 30. April 2026 | N-PORT |
| SBIO · ALPS ETF Trust | 0,74% | 317.578 NS | 31. Mai 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,53% | 29.662 SH | 19. August 2026 | Täglich |
| AGNG · Global X Funds | 0,46% | 98.947 NS | 31. Mai 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,34% | 625.921 NS | 30. April 2026 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0,11% | 64.525 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 0,09% | 2.194.293 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 17.098 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 330.117 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,08% | 2.783.818 SH | 19. August 2026 | Täglich |
| PSC · Principal Exchange-Traded Funds | 0,07% | 354.917 NS | 30. Juni 2026 | N-PORT |
| ESML · iShares Trust | 0,06% | 447.380 SH | 19. August 2026 | Täglich |
| BIB · ProShares Trust | 0,06% | 11.389 NS | 31. Mai 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 114.273 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 1.771.496 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,04% | 7.900.932 SH | 19. August 2026 | Täglich |
| ISCG · iShares Trust | 0,04% | 94.032 SH | 19. August 2026 | Täglich |
| ITWO · ProShares Trust | 0,03% | 14.400 NS | 31. Mai 2026 | N-PORT |
| RSSL · Global X Funds | 0,03% | 132.607 NS | 30. April 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 1.466.402 NS | 31. Mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 61.465 NS | 31. Mai 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,02% | 874.372 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | 0,02% | 13.557 SH | 19. August 2026 | Täglich |
| UWM · ProShares Trust | 0,02% | 11.261 NS | 31. Mai 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 135.688 NS | 30. April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 638.128 NS | 30. April 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 11.390 NS | 31. Mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3.543.398 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 16.464 SH | 19. August 2026 | Täglich |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 12.000 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 286 NS | 31. Mai 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 452.118 NS | 30. April 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 27.701 NS | 30. April 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 466.285 SH | 19. August 2026 | Täglich |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 1.330 NS | 31. Mai 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 83.490 SH | 19. August 2026 | Täglich |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 196.006 NS | 31. Mai 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 10.345 NS | 30. April 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 32.093 NS | 30. April 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 14.557 NS | 30. April 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9.327.332 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 26.184 SH | 19. August 2026 | Täglich |